Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Sotera Health on Pace for Largest Percent Decrease Since April 2025 -- Data Talk

Sotera Health on Pace for Largest Percent Decrease Since April 2025 -- Data Talk

Dow JonesDow Jones2026/11/03 16:08

Sotera Health Company (SHC) is currently at $16.80, down $0.94 or 5.3%

--Would be lowest close since June 24, 2026, when it closed at $16.69

--On pace for largest percent decrease since April 10, 2025, when it fell 6.36%

--Currently down three consecutive days; down 10.16% over this period

--Worst three day stretch since the three days ending April 7, 2025, when it fell 11.04%

--Down 4.76% year-to-date; on pace for worst year since 2024, when it fell 18.81%

--Down 42.03% from its all-time closing high of $28.98 on March 12, 2021

--Up 2.25% from 52 weeks ago (Nov. 4, 2025), when it closed at $16.43

--Down 14.15% from its 52-week closing high of $19.57 on Aug. 21, 2026

--Up 27.95% from its 52-week closing low of $13.13 on March 27, 2026

--Traded as low as $16.41; lowest intraday level since June 24, 2026, when it hit $15.98

--Down 7.51% at today's intraday low; largest intraday percent decrease since April 10, 2025, when it fell as much as 8.57%

All data as of 11:04:14 AM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

November 03, 2026 11:08 ET (16:08 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss